 | | Vol. 11.21 – 2 June, 2022 |
| |
|
|
| The authors showed that ω-3 fatty acid-derived epoxides released from mast cells by PAF-AH2, an oxidized phospholipid-selective phospholipase A2, negatively regulated pulmonary hypertension.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated the antagonist effects of the conserved coronavirus endoribonuclease, in combination with NS4a or NS4b.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators reported a comparative analysis by TempoSeq, oligo-directed sequencing, of an iPSC-derived airway model with a primary bronchial airway model.
[Cell Biology and Toxicology] |
|
|
|
| Scientists retrospectively analyzed the clinical, histopathological, and molecular data of 3,254 Chinese patients with preinvasive lesions, minimally invasive adenocarcinomas, and invasive lung adenocarcinoma. Molecular data were elucidated using a targeted 68-gene next-generation sequencing panel.
[Modern Pathology] |
|
|
|
| Researchers investigated the role of the lysosomal vacuolar ATPase B2 subunit in oxidative stress-induced alveolar epithelial cell death and in an experimental lung injury/fibrosis model.
[Experimental & Molecular Medicine] |
|
|
|
| The authors conducted infection experiments in bronchial organoids (BO) and an BO-derived air-liquid interface model using eight SARS-CoV-2 variants.
[Communications Biology] |
|
|
|
| Scientists established a method of coating osmium thin film on pathological tissue specimens using plasma chemical vapor deposition technology. They compared asthma-induced mice with Amphiregulin knockout mice.
[Scientific Reports] |
|
|
|
| Investigators demonstrated that cigarette smoke extract could induce imbalanced vasoactive prostanoid release by differentially modulating the expression of respective synthase genes in human pulmonary artery smooth muscle cells and endothelial cells, thereby contributing to cell proliferation.
[Respiratory Research] |
| | Scientists demonstrated that Raman spectroscopy was an in situ, real-time, and rapid detection method for detecting metabolites, especially suitable for the assignment of phenylalanine/tyrosine and nucleotides, which play important roles in cellular growth.
[Environmental Science and Pollution Research] |
| LUNG CANCER |
|
|
| Ankyrin repeat domain 49 (ANKRD49) protein in lung squamous cell carcinoma versus paired noncancerous lung tissues was tested and its clinical significance was evaluated through χ2 test, log-rank test, and Cox proportional hazards model.
[Applied Immunohistochemistry & Molecular Morphology] |
|
|
|
| The authors demonstrated that the interaction of the platelet isoform of phosphofructokinase 1 (PFKP) and AMP-activated protein kinase (AMPK) was greatly enhanced upon glucose starvation, a process regulated by PFKP-associated metabolites.
[Cell Discovery] |
|
|
|
| Scientists screened a patient-derived xenograft library to identify small cell lung cancer as a tumor type with enhanced sensitivity to calicheamicin antibody–drug conjugates. They developed an antibody targeting seizure-related homolog 6 (SEZ6) that is rapidly internalized upon receptor binding and, when conjugated to the calicheamicin linker drug, drives potent tumor regression in vitro and in vivo.
[Molecular Cancer therapeutics] |
|
|
|
|
| Investigators summarize the potential mechanisms driving the beneficial effects of baicalin and baicalein treatment on pulmonary hypertension, including anti-inflammatory response, inhibition of pulmonary smooth muscle cell proliferation, stabilization of the extracellular matrix, and mitigation of oxidative stress.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| Instil Bio, Inc. announced Investigational New Drug (IND) clearance by the US FDA of ITIL-306, Instil’s first genetically-engineered Costimulatory Antigen Receptor TIL (CoStAR-TIL) therapy.
[Instil Bio, Inc.] |
|
|
|
| Tvardi Therapeutics, Inc. announced that its lead product, TTI-101, has been granted Orphan Drug Designation by the US FDA for the treatment of idiopathic pulmonary fibrosis.
[Tvardi Therapeutics, Inc. (Business Wire, Inc.)] |
|
|
|
|
| June 26 – 28, 2022
Basel, Switzerland |
|
|
|
|
|
| | Norwegian University of Science and Technology -Trondheim, Norway |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
| | Francis Crick Institute – London, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
